The popularity of GLP-1 agonists to treat obesity has been skyrocketing in recent months, leading to both shortages and price increases. However, as more patients make their voices heard and doctors begin to prescribe them, obesity could become easier to treat or even cure. Thanksgiving is a time for family, fellowship, and food. But for...
I’m so proud of the news presence the Society has built and the coverage we have had over the last few months related to our Obesity Science Writers Conference and our advocacy efforts. We are regularly featured in the news for our research and advocacy. Reporters rely on our members’ expertise on various endocrine health...
Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world’s smallest, thinnest, and most discreet glucose sensor. With the FDA’s clearance of a standalone reader, Abbott is working to get the FreeStyle Libre 3 system added to Medicare’s...Glytec Announces Next Evolution of GlucoMetrics as Hospitals Prepare for New CMS Measures
Glytec today announced the next evolution of GlucoMetricsⓇ to provide new analytics, dashboards, and data visualizations that give hospitals and health systems new insight into glycemic outcomes. The enhanced visibility comes as hospitals prepare for new measures from the Centers for Medicare and Medicaid Services (CMS) on severe hypoglycemia and hyperglycemia that encourage facilities to report metrics starting...
CMS Finalizes Proposal to Expand Coverage of Continuous Glucose Monitors
We are pleased to report the Centers for Medicare & Medicaid Services (CMS) finalized policy that will expand coverage of Continuous Glucose Monitors (CGM) and incorporated Endocrine Society recommendations. The final local coverage determination (LCD) expands CGM coverage for all people with diabetes with any type or manner of insulin treatment. The policy also will...
Therapeutic program targets a novel mechanism of melatonin receptor action outside of the CNS Celmatix Inc. today announced its latest drug program that targets melatonin receptors outside of the central nervous system (CNS). The company hopes the therapeutic drug will address a critical gap in the market for effective first-line treatments for a range of...
Last month, three of the largest insulin manufacturers announced they would take steps to reduce the price of their insulins. Eli Lilly and Company first announced it would reduce the list price for certain insulins by 70% and extend the $35 per month cap on out-of-pocket costs for people with Medicare that was enacted in...
Endocrine Society Releases Educational Resource on Obesity for Congress
Obesity is a public health crisis in the United States. As a prevalent and costly disease, it puts adults and children at risk for many comorbid conditions, reduces productivity, and impairs military readiness. As the 118th Congress gets underway, several congressional leaders and committees are interested in addressing obesity in America. In March, as part...
